Get started
Work

In vitro activity of clindamycin, doxycycline, and trimethoprim/sulfamethoxazole against clinical isolates of β-hemolytic Streptococcus spp. via BD Phoenix and broth microdilution

Year: 2023
Type: article
Abstract: We tested 85 isolates of β-hemolytic Streptococcus spp. against trimethoprim/sulfamethoxazole (TMP/SMX), clindamycin, and doxycycline by broth microdilution (BMD) and BD Phoenix. Susceptibility rates via BMD for TMP/SMX, clindamycin, and doxycycline were 100%, 85.5%, and 56.6%, respectively. TMP/SMX is a potential monotherapy agent for β-hemolytic Streptococcus skin and soft tissue infections.
DOI: 10.1017/ash.2023.515
Authors: Christian Cho, Ryan K Shields, Ellen G Kline, Thomas L. Walsh, Chelsea E. Jones, Karen Kasarda, Kelly Stefano, Matthew A. Moffa, Derek N. Bremmer
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,200
OpenAlex ID: W4389790190
FWCI: 1.536
Cites: 7
Cited by: 6
Related to: 10